Overview

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Status:
Terminated
Trial end date:
2021-02-05
Target enrollment:
Participant gender:
Summary
This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.
Phase:
Early Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Edotreotide
Octreotide